Browse by author
Lookup NU author(s): Alice Lin, Dr Faye Cooles, Professor John IsaacsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022, Springer Nature Limited.For many oncological conditions, the application of timely and patient-tailored targeted therapies, or precision medicine, is a major therapeutic development that has provided considerable clinical benefit. However, despite the application of increasingly sophisticated technologies, alongside advanced bioinformatic and machine-learning algorithms, this success is yet to be replicated for the rheumatic diseases. In rheumatoid arthritis, for example, despite an array of targeted biologic and conventional therapeutics, treatment choice remains largely based on trial and error. The concept of the ‘precision gap’ for rheumatic disease can help us to identify factors that underpin the slow progress towards the discovery and adoption of precision-medicine approaches for rheumatic disease. In a rheumatic disease such as rheumatoid arthritis, it is possible to identify four themes that have slowed progress, solutions to which should help to close the precision gap. These themes relate to our fundamental understanding of disease pathogenesis, how we determine treatment response, confounders of treatment outcomes and trial design.
Author(s): Lin CMA, Cooles FAH, Isaacs JD
Publication type: Article
Publication status: Published
Journal: Nature Reviews Rheumatology
Year: 2022
Volume: 18
Pages: 725-733
Print publication date: 01/12/2022
Online publication date: 10/10/2022
Acceptance date: 07/09/2022
ISSN (print): 1759-4790
ISSN (electronic): 1759-4804
Publisher: Nature Research
URL: https://doi.org/10.1038/s41584-022-00845-w
DOI: 10.1038/s41584-022-00845-w
PubMed id: 36216923
Altmetrics provided by Altmetric